255 related articles for article (PubMed ID: 25760977)
1. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.
Caffo O; Lo Re G; Sava T; Buti S; Sacco C; Basso U; Zustovich F; Lodde M; Perin A; Facchini G; Veccia A; Maines F; Barile C; Fratino L; Gernone A; De Vivo R; Pappagallo GL; Galligioni E
Future Oncol; 2015; 11(6):965-73. PubMed ID: 25760977
[TBL] [Abstract][Full Text] [Related]
2. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.
Veccia A; Caffo O; De Giorgi U; Di Lorenzo G; Ortega C; Scognamiglio F; Aieta M; Facchini G; Mansueto G; Mattioli R; Procopio G; Zagonel V; D'Angelo A; Spizzo G; Bortolus R; Donini M; Lo Re G; Massari F; Vicario G; Zucali PA; Alesini D; Bonetti A; Mucciarini C; Nicodemo M; Berruti A; Fratino L; Lodde M; Messina C; Perin A; Santini D; Sava T; Tucci M; Basso U; Maines F; Burgio LS; Galligioni E
Future Oncol; 2016 Feb; 12(4):493-502. PubMed ID: 26776493
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Petrylak DP; Vogelzang NJ; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; de Olza MO; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; Van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; de Wit R; Fizazi K
Lancet Oncol; 2015 Apr; 16(4):417-25. PubMed ID: 25743937
[TBL] [Abstract][Full Text] [Related]
5. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Du J; Yang Q; Chen XS; Tian J; Yao X
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
[TBL] [Abstract][Full Text] [Related]
6. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Singal R; Ramachandran K; Gordian E; Quintero C; Zhao W; Reis IM
Clin Genitourin Cancer; 2015 Feb; 13(1):22-31. PubMed ID: 25178642
[TBL] [Abstract][Full Text] [Related]
9. Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer.
Gyawali B; Koomulli-Parambil S; Iddawela M
Crit Rev Oncol Hematol; 2016 Jun; 102():118-24. PubMed ID: 27157868
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Derosa L; Galli L; Orlandi P; Fioravanti A; Di Desidero T; Fontana A; Antonuzzo A; Biasco E; Farnesi A; Marconcini R; Francia G; Danesi R; Falcone A; Bocci G
Cancer; 2014 Dec; 120(24):3923-31. PubMed ID: 25111199
[TBL] [Abstract][Full Text] [Related]
11. Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer.
Emmenegger U; Booth CM; Berry S; Sridhar SS; Winquist E; Bandali N; Chow A; Lee C; Xu P; Man S; Kerbel RS; Ko YJ
Oncologist; 2015 Dec; 20(12):1351-2. PubMed ID: 26542984
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.
Courtney KD; Manola JB; Elfiky AA; Ross R; Oh WK; Yap JT; Van den Abbeele AD; Ryan CW; Beer TM; Loda M; Priolo C; Kantoff P; Taplin ME
Clin Genitourin Cancer; 2015 Apr; 13(2):113-23. PubMed ID: 25450031
[TBL] [Abstract][Full Text] [Related]
13. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.
Schutz FA; Buzaid AC; Sartor O
Crit Rev Oncol Hematol; 2014 Sep; 91(3):248-56. PubMed ID: 24613528
[TBL] [Abstract][Full Text] [Related]
14. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
[TBL] [Abstract][Full Text] [Related]
15. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Dreicer R
Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
[No Abstract] [Full Text] [Related]
16. Docetaxel in castration-resistant prostate cancer: a single-centre experience.
Detti B; Franceschini D; Saieva C; Di Brina L; Baki M; Meattini I; Di Cataldo V; Pasquetti EM; Furfaro I; Mancuso A; Simontacchi G; Livi L
Cancer Invest; 2014 Nov; 32(9):445-50. PubMed ID: 25259606
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.
Bracarda S; Caserta C; Galli L; Carlini P; Pastina I; Sisani M; Scali S; Hamzaj A; Derosa L; Felici A; Rossi M; Altavilla A; Chioni A; De Angelis V
Future Oncol; 2015 Nov; 11(22):3083-90. PubMed ID: 26437324
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel in the treatment of castrate resistant advanced prostate cancer: a paradigm in change.
Dediu M; Bratu F; Amarandei M; Fejer E
J BUON; 2016; 21(6):1379-1382. PubMed ID: 28039695
[TBL] [Abstract][Full Text] [Related]
19. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer.
Mountzios I; Bournakis E; Efstathiou E; Varkaris A; Wen S; Chrisofos M; Deliveliotis C; Alamanis C; Anastasiou I; Constantinides C; Karadimou A; Tsiatas M; Papadimitriou C; Bamias A; Dimopoulos MA
Urology; 2011 Mar; 77(3):682-7. PubMed ID: 21256546
[TBL] [Abstract][Full Text] [Related]
20. Drug therapies for metastatic castration-resistant prostate cancer.
El-Bahesh E; Finianos A; Alfaraj A; Aragon-Ching JB
Future Oncol; 2015; 11(17):2395-403. PubMed ID: 26274603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
